Ephrin Receptor
-
Ephrin Receptor Related Products (37)
Related Products (37)
- 1
- 2
-
LDN-211904
0 ImagesCat. No.: HY-136358CAS No.: 1198408-39-7LDN-211904 is a potent and reversible EphB3 inhibitor with an IC50 of 79 nM. LDN-211904 shows good metabolic stability in mouse liver microsomes. LDN-211904 with cetuximab could be effective in inhibiting STAT3-activated colorectal cancer (CRC) stemness and Cetuximab (HY-P9905) resistance in CRC.
-
150D4
0 ImagesCat. No.: HY-P11244CAS No.: 2866306-73-0150D4 is an efficient, selective, and blood-brain barrier penetrable EphA4 agonist. 150D4 has excitatory activity and neuroprotective effects. 150D4 can be used for research on neurological conditions.
-
A11 acetate
0 ImagesCat. No.: HY-P10412APurity: 98.48%Synonyms: ANXA1-derived 11 amino acid-long peptide acetateA11 (ANXA1-derived 11 amino acid-long peptide) acetate is a ANXA1-EphA2 interaction-blocking peptide. A11 acetate reduces ANXA1 bound to EphA2 and increases Cbl (the E3 ubiquitin ligase of EphA2) bound to EphA2. A11 acetate inhibits the proliferation, migration and invasion of nasopharyngeal carcinoma cells. A11 acetate inhibits angiogenesis. A11 acetate can be used in studies related to nasopharyngeal carcinoma.
-
Urolithin D (Standard)
0 ImagesCat. No.: HY-133178RCAS No.: 131086-98-1Synonyms: 3,4,8,9-Tetrahydroxy urolithin (Standard)Urolithin D (Standard) (3,4,8,9-Tetrahydroxy urolithin (Standard)) is the analytical standard of Urolithin D (HY-133178). This product is intended for research and analytical applications. Urolithin D (3,4,8,9-Tetrahydroxy urolithin) is a colonic metabolite of Ellagitannins and a competitive, reversible, and selective antagonist of the EphA receptor. Urolithin D inhibits EphA2-ephrin-A1 binding with an IC50 of 0.9 μM. Urolithin D is also a potent antioxidant that scavenges free radicals and repairs oxidized DNA damage. Additionally, Urolithin D suppresses triglyceride accumulation and promotes fatty acid oxidation by activating the AMPK signaling pathway. Urolithin D can be used for research on tumors, metabolic, and inflammatory diseases.
-
Anti-EphB3 Antibody
0 ImagesCat. No.: HY-P991975
-
Antimalarial agent 37
0 ImagesCat. No.: HY-161171CAS No.: 2982633-16-7Antimalarial agent 37 (compound 33) is a selective inhibitor against Type Ⅱ kinase with antiplasmodial activity. Antimalarial agent 37 exhibited cytotoxicity and selectivity towards cancer cells HepG2 and MCF 7.
-
Nastorazepide hemicalcium
0 ImagesCat. No.: HY-14575CAS No.: 343326-69-2Synonyms: Z-360 hemicalciumNastorazepide (Z-360) hemicalcium is an orally active 1,5-benzodiazepine derivative and gastrin/CCK-2 receptor antagonist. Nastorazepide hemicalcium inhibits the specific binding of [3H]CCK-8 to the human CCK-2 receptor with a Ki value of 0.47 nM. Nastorazepide hemicalcium inhibits IL-1β, ephrin B1, VEGF, and HIF-1alpha, reduces Akt and NR2B phosphorylation. Nastorazepide hemicalcium has antitumor activity against pancreatic cancer. Nastorazepide hemicalcium inhibits colorectal cancer liver metastasis and relieves pain.
-
Anti-Ephrin-B2 Antibody
0 ImagesCat. No.: HY-P991965
-
ML786
0 ImagesCat. No.: HY-14979CAS No.: 1237586-97-8
-
Multi-kinase-IN-12
0 ImagesCat. No.: HY-18692CAS No.: 597544-21-3Multi-kinase-IN-12 is a non-selective multi-target inhibitor, with IC50 values against human targets as follows: Flt3 < 0.001 μM, c-Src 0.002 μM, KDR 0.004 μM, Eph-A2, MNK-1 and Flt1 0.011 μM, Lck 0.016 μM, Rsk1 0.21 μM, and α2 subunit of AMPK 0.041 μM. Multi-kinase-IN-12 can be used in research related to solid tumors.
-
EPHB4 modulator-1
0 ImagesCat. No.: HY-186005CAS No.: 633281-74-0
-
LDN-211904 oxalate (Standard)
0 ImagesCat. No.: HY-107460RCAS No.: 1198408-78-4LDN-211904 oxalate (Standard) is the analytical standard of LDN-211904 (oxalate) (HY-107460). This product is intended for research and analytical applications. LDN-211904 oxalate is a potent and reversible EphB3 inhibitor with an IC50 of 79 nM. LDN-211904 oxalate shows good metabolic stability in mouse liver microsomes. LDN-211904 oxalate with Cetuximab (HY-P9905) could be effective in inhibiting STAT3-activated colorectal cancer (CRC) stemness and Cetuximab resistance in CRC.
-
Anti-EPHA4 Antibody
0 ImagesCat. No.: HY-P991974
-
Nastorazepide (Standard)
0 ImagesCat. No.: HY-17617RCAS No.: 209219-38-5Synonyms: Z-360 (Standard)Nastorazepide (Standard) is the analytical standard of Nastorazepide. This product is intended for research and analytical applications. Nastorazepide (Z-360) is an orally active 1,5-benzodiazepine derivative and gastrin/CCK-2 receptor antagonist. Nastorazepide inhibits the specific binding of [3H]CCK-8 to the human CCK-2 receptor with a Ki value of 0.47 nM. Nastorazepide inhibits IL-1β, ephrin B1, VEGF, and HIF-1alpha, reduces Akt and NR2B phosphorylation. Nastorazepide has antitumor activity against pancreatic cancer. Nastorazepide inhibits colorectal cancer liver metastasis and relieves pain.
- 1
- 2
